[
  {
    "ts": "2025-07-31T17:20:00+00:00",
    "headline": "Cigna Q2 Earnings Beat Estimates on Higher Specialty Volumes",
    "summary": "CI's Q2 earnings benefit from strong Evernorth Health Services unit, offsetting customer losses and rising costs. It continues to expect 2025 adjusted EPS at a minimum of $29.60.",
    "url": "https://finance.yahoo.com/news/cigna-q2-earnings-beat-estimates-172000336.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3ca2c2f6-5f25-3526-9b23-8712f5409f1f",
      "content": {
        "id": "3ca2c2f6-5f25-3526-9b23-8712f5409f1f",
        "contentType": "STORY",
        "title": "Cigna Q2 Earnings Beat Estimates on Higher Specialty Volumes",
        "description": "",
        "summary": "CI's Q2 earnings benefit from strong Evernorth Health Services unit, offsetting customer losses and rising costs. It continues to expect 2025 adjusted EPS at a minimum of $29.60.",
        "pubDate": "2025-07-31T17:20:00Z",
        "displayTime": "2025-07-31T17:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5298e8fb1dbd1ae52f8b9876f685ed31",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VV1V8Zk0hdPY7hDlUr2slw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5298e8fb1dbd1ae52f8b9876f685ed31.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I1fLSAEHImn7RJTjYyjeGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5298e8fb1dbd1ae52f8b9876f685ed31.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cigna-q2-earnings-beat-estimates-172000336.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cigna-q2-earnings-beat-estimates-172000336.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            },
            {
              "symbol": "UHS"
            },
            {
              "symbol": "CI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-31T15:01:00+00:00",
    "headline": "BioHub Maryland, Powered by the Maryland Tech Council, Welcomes Cutting-Edge Contributions from Biopharma Industry Leaders",
    "summary": "ROCKVILLE, Md., July 31, 2025--BioHub Maryland, powered by the Maryland Tech Council, is pleased to announce that over a dozen biopharmaceutical industry leaders have gifted critical and cutting-edge equipment to the BioHub Maryland Training and Education Center at Montgomery County. The contributions enhance BioHub Maryland’s immersive, lab-based workforce training at the 8,200 square-foot facility in Rockville that is designed to replicate real-world biopharma production environments.",
    "url": "https://finance.yahoo.com/news/biohub-maryland-powered-maryland-tech-150100515.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "50a8a0dc-94c2-36ca-818e-822a8e554875",
      "content": {
        "id": "50a8a0dc-94c2-36ca-818e-822a8e554875",
        "contentType": "STORY",
        "title": "BioHub Maryland, Powered by the Maryland Tech Council, Welcomes Cutting-Edge Contributions from Biopharma Industry Leaders",
        "description": "",
        "summary": "ROCKVILLE, Md., July 31, 2025--BioHub Maryland, powered by the Maryland Tech Council, is pleased to announce that over a dozen biopharmaceutical industry leaders have gifted critical and cutting-edge equipment to the BioHub Maryland Training and Education Center at Montgomery County. The contributions enhance BioHub Maryland’s immersive, lab-based workforce training at the 8,200 square-foot facility in Rockville that is designed to replicate real-world biopharma production environments.",
        "pubDate": "2025-07-31T15:01:00Z",
        "displayTime": "2025-07-31T15:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/2629713031cd2a8adc62d74dffacc9d2",
          "originalWidth": 480,
          "originalHeight": 259,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pfuY_1hqAPEPKZm2qYWjvg--~B/aD0yNTk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2629713031cd2a8adc62d74dffacc9d2.cf.webp",
              "width": 480,
              "height": 259,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Mdmw9hsnHNVN1qzEqftc6g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2629713031cd2a8adc62d74dffacc9d2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biohub-maryland-powered-maryland-tech-150100515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biohub-maryland-powered-maryland-tech-150100515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-31T12:30:10+00:00",
    "headline": "Here’s Why Thermo Fisher Scientific (TMO) Traded Down in Q2",
    "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care […]",
    "url": "https://finance.yahoo.com/news/why-thermo-fisher-scientific-tmo-123010754.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "884ce1a5-5f35-31a5-afd2-2c815c6bedd2",
      "content": {
        "id": "884ce1a5-5f35-31a5-afd2-2c815c6bedd2",
        "contentType": "STORY",
        "title": "Here’s Why Thermo Fisher Scientific (TMO) Traded Down in Q2",
        "description": "",
        "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care […]",
        "pubDate": "2025-07-31T12:30:10Z",
        "displayTime": "2025-07-31T12:30:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4505f322faedfbfafb576fe4b20bd921",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Thermo Fisher Scientific’s (TMO) Dividend: Steady Payouts in a Growing Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t09qF4JVyCHBUYhbTpriVA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4505f322faedfbfafb576fe4b20bd921.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/anwOpxdO_.7889BHm6WJ1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4505f322faedfbfafb576fe4b20bd921.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-thermo-fisher-scientific-tmo-123010754.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-thermo-fisher-scientific-tmo-123010754.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-31T09:41:00+00:00",
    "headline": "Systemic Lupus Erythematosus Clinical Trials Market Landscape Report 2025 Featuring GSK, BMS, AstraZeneca, Thermo Fisher Scientific, ICON, IQVIA, Parexel, Laboratory Corp of America, Novartis, Pfizer",
    "summary": "Discover comprehensive insights into the global Systemic Lupus Erythematosus clinical trials landscape with the \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\". The report offers detailed analyses of trial data by region, country, phase, status, and sponsor type, assisting in strategic planning and competitive positioning.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\" clinical trials has been added to Resear",
    "url": "https://finance.yahoo.com/news/systemic-lupus-erythematosus-clinical-trials-094100501.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "956431b5-e4b7-3db0-baa5-0181e097c3e0",
      "content": {
        "id": "956431b5-e4b7-3db0-baa5-0181e097c3e0",
        "contentType": "STORY",
        "title": "Systemic Lupus Erythematosus Clinical Trials Market Landscape Report 2025 Featuring GSK, BMS, AstraZeneca, Thermo Fisher Scientific, ICON, IQVIA, Parexel, Laboratory Corp of America, Novartis, Pfizer",
        "description": "",
        "summary": "Discover comprehensive insights into the global Systemic Lupus Erythematosus clinical trials landscape with the \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\". The report offers detailed analyses of trial data by region, country, phase, status, and sponsor type, assisting in strategic planning and competitive positioning.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\" clinical trials has been added to Resear",
        "pubDate": "2025-07-31T09:41:00Z",
        "displayTime": "2025-07-31T09:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/systemic-lupus-erythematosus-clinical-trials-094100501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/systemic-lupus-erythematosus-clinical-trials-094100501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-31T09:38:00+00:00",
    "headline": "Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health",
    "summary": "Discover key insights with the \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025.\" This comprehensive report offers top-line data on Sicca Syndrome (Sjogren) trials worldwide, covering trial numbers, enrollment, regions, phases, and sponsors. Enhance decision-making and gain a competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical",
    "url": "https://finance.yahoo.com/news/sicca-syndrome-sjogren-clinical-trials-093800574.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e2192ff4-3391-3bf9-9b6c-7349e7c289ec",
      "content": {
        "id": "e2192ff4-3391-3bf9-9b6c-7349e7c289ec",
        "contentType": "STORY",
        "title": "Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health",
        "description": "",
        "summary": "Discover key insights with the \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025.\" This comprehensive report offers top-line data on Sicca Syndrome (Sjogren) trials worldwide, covering trial numbers, enrollment, regions, phases, and sponsors. Enhance decision-making and gain a competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical",
        "pubDate": "2025-07-31T09:38:00Z",
        "displayTime": "2025-07-31T09:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sicca-syndrome-sjogren-clinical-trials-093800574.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sicca-syndrome-sjogren-clinical-trials-093800574.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]